Tanner of Lazard did give a price target of $11/share and many here are hung up on the fact that the price did not jump instantly to $11. Everyone is forgetting the rest of what he said. He spoke of the RSV program as "one of the most underappreciated assets in the Industry". Nothing has changed that fact; yet. At some point it will become widely known, and every institution and their mother will want this stock. In the meantime, put your feet up and enjoy the ride. Just be sure to be quick to buckle your seat belt because when it takes off, you'll be in for the ride of your life.
Novavax rallies after analyst says vaccine potential undervalued
Shares of Novavax (NVAX) are jumping after Lazard Capital analyst William Tanner wrote that the company's vaccine against a prevalent respiratory virus could be more effective than a competing product. The vaccine "could be one of the most underappreciated assets in the industry," added Tanner, who increased his price target on the shares to $11 from $4. WHAT'S NEW: Novax's vaccine against respiratory syncytial virus, or RSV, could be more effective than a competing product, Synagis, Tanner wrote in a note to investors earlier today. RSV causes inflammation of the bronchioles and is a common cause of pneumonia among infants and children who are less than a year old. Synagis has several limitations, including a high price tag, and Novavax's vaccine may prevent RSV infection in a broader population of babies and in the elderly, Tanner contended. Despite Synagis' limitations, the drug generated about $1B in revenue last year, demonstrating that an RSV vaccine can be lucrative.